Top

Published in:

01-10-2016

Apolipoprotein E ε4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals

Authors: Sarah A. Cooley, Robert H. Paul, Christine Fennema-Notestine, Erin E. Morgan, Florin Vaida, Qianqian Deng, Jie Ashley Chen, Scott Letendre, Ronald Ellis, David B. Clifford, Christina M. Marra, Ann C. Collier, Benjamin B. Gelman, Justin C. McArthur, J. Allen McCutchan, David M. Simpson, Susan Morgello, Igor Grant, Beau M. Ances, for the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) Group

Published in: Journal of NeuroVirology | Issue 5/2016

Abstract

Previous neuroimaging studies suggest a negative relationship between the apolipoprotein (ApoE) ε4 allele and brain integrity in human immunodeficiency virus (HIV)-infected (HIV+) individuals, although the presence of this relationship across adulthood remains unclear. The purpose of this study is to clarify the discrepancies using a large, diverse group of HIV+ individuals and multiple imaging modalities sensitive to HIV. The association of ApoE ε4 with structural neuroimaging and magnetic resonance spectroscopy (MRS) was examined in 237 HIV+ individuals in the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) study. Cortical and subcortical gray matter, abnormal and total white matter, ventricles, sulcal cerebrospinal fluid (CSF), and cerebellar gray matter, white matter, and CSF volumes, and MRS concentrations of myo-inositol, creatine, N-acetyl-aspartate, and choline in the frontal white matter (FWM), frontal gray matter (FGM), and basal ganglia were examined. Secondary analyses explored this relationship separately in individuals ≥50 years old (n = 173) and <50 years old (n = 63). No significant differences were observed between ApoE ε4+ (ApoE ε3/ε4 and ApoE ε4/ε4) individuals (n = 69) and ApoE ε4− (ApoE ε2/ε3 and ApoE ε3/ε3) individuals (n = 167). When individuals were further divided by age, no significant genotype group differences were identified in individuals <50 or ≥50 years of age on any neuroimaging outcome. The ApoE ε4 allele did not affect brain integrity in this large, diverse sample of HIV+ individuals. The effects of ApoE ε4 may not be apparent until more advanced ages and may be more prominent when present along with other risk factors for neuronal damage.

Ances BM, Ortega M, Vaida F, Heaps J, Paul RH (2012) Independent effects of HIV, aging, and HAART on brain volumetric measures. J Acquir Immune Defic Syndr 59:469–477CrossRefPubMedPubMedCentral

Anderson AM, Fennema-Notestine C, Umlauf A, Taylor MJ, Clifford DB, Marra CM, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Simpson DM, Morgello S, Grant I, Letendre SL, CHARTER Group (2015) CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease. J Neurovirol 1:9

Becker JT, Martinson JJ, Penugonda S, Kingsley L, Molsberry S, Reynolds S, Aronow A, Goodkin K, Levine A, Martin E, Miller EN, Munro CA, Ragin A, Sacktor N (2014) No association between Apoε4 alleles, HIV infection, age, neuropsychological outcome, or death. J Neurovirol 21:24–31CrossRefPubMedPubMedCentral

Brummel SS, Singh KK, Maihofer AX, Farhad M, Qin M, Fenton T, Nievergelt CM, Spector SA (2016). Associations of genetically determined continental ancestry with CD4+ count and plasma HIV-1 RNA beyond self-reported race and ethnicity. JAIDS, Advance online publication. doi:10.1097/QAI.0000000000000883

Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, Cavrois M, Huang Y, Mahley RW, Dolan MJ, McCune JM, Ahuja SK (2008) Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro and the APOE ε4/ε4 genotype accelerates HIV disease progression. PNAS 105:8718–8723CrossRefPubMedPubMedCentral

Chang L, Andres M, Sadino J, Jiang CS, Nakama H, Miller E, Ernst T (2011) Impact of apolipoprotein E ε4 and HIV on cognition and brain atrophy: antagonistic pleiotropy and premature brain aging. Neuroimage 58:1017–1027CrossRefPubMedPubMedCentral

Chang L, Jiang C, Cunningham E, Buchthal S, Douet V, Andres M, Ernst T (2014) Effects of APOE ε4, age, and HIV on glial metabolites and cognitive deficits. Neurology 82:2213–2222CrossRefPubMedPubMedCentral

Cohen RA, Harezlak J, Schifitto G, Hana G, Clark U, Gongvatana A, Paul RH, Taylor M, Thompson P, Alger J, Brown M, Zhong J, Campbell T, Singer E, Daar E, McMahon D, Tso Y, Yiannoutsos CT, Navia B, HIV Neuroimaging Consortium (2010) Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neurovirol 16:25–32CrossRefPubMedPubMedCentral

Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261:921–923CrossRefPubMed

Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC (2002) Apoliprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 155:487–495CrossRefPubMed

Ernst T, Chang L, Arnold S (2003) Increased glial metabolites predict increased working memory network in HIV brain injury. Neuroimage 19:1686–1693CrossRefPubMed

Fennema-Notestine C, Panizzon MS, Thompson WR, Chen CH, Eyler LT, Fischl B, Franz CE, Grant MD, Jak AJ, Jernigan TL, Lyons MJ, Neale MC, Seidman LJ, Tsuang MT, Xian H, Dale AM, Kremen WS (2011) Presence of ApoE ε4 allele associated with thinner frontal cortex in middle age. J Alzheimers Dis 26:49–60PubMedPubMedCentral

Fennema-Notestine C, Ellis RJ, Archibald SL, Jernigan TL, Letendre SL, Notestine RJ, Taylor MJ, Theilmann RJ, Julaton MD, Croteau DJ, Wolfson T, Heaton RK, Gamst AC, Franklin DR Jr, Clifford DB, Collier AC, Gelman BB, Marra C, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Grant I, CHARTER Group (2013) Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. J Neurovirol 19:393–401CrossRefPubMedPubMedCentral

Fujimura JH, Rajagopalan R (2011) Different differences: the use of ‘genetic ancestry’ versus race in biomedical human genetic research. Soc Stud Sci 41:5–30CrossRefPubMedPubMedCentral

Gongvatana A, Schweinsburg BC, Taylor MJ, Theilmann RJ, Letendre SL, Alhassoon OM, Jacobus J, Woods SP, Jernigan TL, Ellis RJ, Frank LR, Grant I, CHARTER Group (2009) White matter tract injury and cognitive impairment in HIV-infected individuals. J Neurovirol 15:187–195CrossRefPubMedPubMedCentral

Gongvatana A, Cohen RA, Correia S, Devlin KN, Miles J, Kang H, Ombao H, Navia B, Laidlaw DH, Tashima KT (2011) Clinical contributors to cerebral white matter integrity in HIV-infected individuals. J Neurovirol 17:477–486CrossRefPubMedPubMedCentral

Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar ES, Alger J, Singer E, Campbell T, Yiannoutsos C, Cohen R, Navia BA, HIV Neuroimaging Consortium (2011) Persistence of HIV-associated cognitive impairment, inflammation and neuronal injury in era of highly active antiretroviral treatment. AIDS 25:625–633CrossRefPubMedPubMedCentral

Heaps JM, Joska J, Hoare J, Ortega M, Agrawal A, Seedat S, Ances BM, Stein DJ, Paul RH (2012) Neuroimaging markers of human immunodeficiency virus infection in South Africa. J Neurovirol 18:151–156CrossRefPubMedPubMedCentral

Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75:2087–2096CrossRefPubMedPubMedCentral

Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S, Corkran DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2011) HIV- associated neurocognitive disorder before and during the era of combination antiretroviral therapy: differences in rates, nature and predictors. J Neurovirol 17:3–16CrossRefPubMed

Hoare J, Westgarth-Taylor J, Fouche JP, Combrinck M, Spottiswoode B, Stein DJ, Joska JA (2013) Relationship between apolipoprotein E4 genotype and white matter integrity in HIV-positive young adults in South Africa. Eur Arch Psychiatry Clin Neurosci 263:189–195CrossRefPubMed

Hulgan T, Samuels DC, Bush W, Ellis RJ, Letendre SL, Heaton RK, Franklin DR, Straub P, Murdock DG, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Grant I, Kallianpur AR, CHARTER Study Group (2015) Mitochondrial DNA haplogroups and neurocognitive impairment during HIV infection. Clin Infect Dis 61:1476–1484CrossRefPubMed

Jahanshad N, Valcour VG, Nir TM, Kohannim O, Busovaca E, Nicolas K, Thompson PM (2012) Disrupted brain networks in the aging HIV+ population. Brain Connectivity 2:335–344CrossRefPubMedPubMedCentral

Jernigan TL, Archibald SL, Fennema-Notestine C, Taylor MJ, Teilmann RJ, Julaton MD, Notestine RJ, Wolfson T, Letendre SL, Ellis RJ, Heaton RK, Gamst AC, Franklin DR Jr, Clifford DB, Collier AC, Gelman BB, Marra C, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Grant I, CHARTER Group (2011) Clinical factors related to brain structure in HIV: the CHARTER study. J Neuroviol 17:248–257CrossRef

Joska JA, Combrinck M, Valcour VG, Hoare J, Leisegang F, Mahne AC, Myer L, Stein DJ (2010) Assocation between apolipoprotein E4 genotype and human immunodeficiency virus-associated dementia in younger adults starting antiretroviral therapy in South Africa. J Neurovirol 16:377–383CrossRefPubMed

Kallianpur AR, Jia P, Ellis RJ, Zhao Z, Bloss C, Wen W, Marra CM, Hulgan T, Simpson DM, Morgello S, McArthur JC, Clifford DB, Collier AC, Gelman BB, McCutchan JA, Franklin D, Samuels DC, Rosario D, Holzinger E, Murdock DG, Letendre S, Grant I, CHARTER Study Group (2014) Genetic variation in iron metabolism is associated with neuropathic pain and pain severity in HIV-infected patients on antiretroviral therapy. PLoS One 9:e103123CrossRefPubMedPubMedCentral

Kallianpur AR, Levine AJ (2014) Host genetic factors predisposing to HIV-associated neurocognitive disorder. Curr HIV/AIDS Rep 11:336–352CrossRefPubMedPubMedCentral

Kuhlmann I, Minihane AM, Huebbe P, Nebel A, Rimbach G (2010) Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review. Lipids Health Dis 9:8CrossRefPubMedPubMedCentral

Lin K, Taylor MJ, Heaton R, Franklin D, Jernigan T, Fennema-Notestine C, McCutchan A, Atkinson JH, Ellis RJ, McArthur J, Morgello S, Simpson D, Collier AC, Marra C, Gelman B, Clifford D, Grant I, group C (2011) Effects of traumatic brain injury on cognitive functioning and cerebral metabolites in HIV-infected individuals. J Clin Exp Neuropsychol 33:326–334

Logue MW, Schu M, Vardarajan BN, Buros J, Green RC, Go RCP, Griffith P, Obisesan TO, Shatz R, Borenstein A, Cupples LA, Lunetta KL, Fallin MD, Baldwin CT, Farrer LA, Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (2011) A comprehensive genetic association study of Alzheimer disease in African Americans. Arch Neurol 68:1569–1579CrossRefPubMedPubMedCentral

Martins CAR, Oulhaj A, de Jager CA, Williams JH (2005) APOE alleles predict the rate of cognitive decline in Alzheimer disease. Neurology 65:1888–1893CrossRefPubMed

Masters MC, Ances BM (2014) Role of neuroimaging in HIV-associated neurocognitive disorders. Semin Neurol 34:89–102CrossRefPubMedPubMedCentral

Mersha TB, Abebe T (2015) Self-reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities. Human Genomics 9:1–15CrossRefPubMedPubMedCentral

Morgan EE, Woods SP, Letendre SL, Franklin DR, Bloss C, Goate A, Heaton RK, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Ellis RJ, Abramson I, Gamst A, Fennema-Notestine C, Smith DM, Grant I, Vaida F, Clifford DB, CHARTER Group (2013) Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol 19:150–16CrossRefPubMedPubMedCentral

Murrell JR, Price B, Lane KA, Baiyewu O, Gureje O, Ogunniyi A, Unverzagt FW, Smith-Gamble V, Gao S, Hendrie HC, Hall KS (2006) Association of apolipoprotein E genotype and Alzheimer disease in African Americans. JAMA Neurology 63:431–434

Panos SE, Hinkin CH, Singer EJ, Thames AD, Patel SM, Sinsheimer JS, Del Re AC, Gelman BB, Morgello S, Moore DJ, Levine AJ (2013) Apolipoprotein-E genotype and human immunodeficiency virus-associated neurocognitive disorder: the modulating effects of older age and disease severity. Neurobehavioral HIV Medicine 5:11–22CrossRefPubMedPubMedCentral

Pfefferbaum A, Rogosa DA, Rosenbloom MJ, Chu W, Sassoon SA, Kemper CA, Deresinski S, Rohlfing T, Zahr NM, Sullivan EV (2014) Accelerated aging of selective brain structures in HIV infection: a controlled, longitudinal MRI study. Neurobiol Aging 35:1755–1768CrossRefPubMedPubMedCentral

Pomara N, Crandall DT, Choi SJ, Johnson G, Lim KO (2001) White matter abnormalities in HIV-1 infection: a diffusion tensor imaging study. Psychiatry Res Neuroimaging 106:15–24CrossRefPubMed

Provencher SW (2001) Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 14:260–264CrossRefPubMed

Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136–142CrossRefPubMed

Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR Jr, Weiner MW, Alzheimer’s Disease Neuroimaging Initiative (2009) MRI of hippocampal volume loss in early Alzheimer’s disease in relation to ApoE genotype and biomarkers. Brain 132:1067–1077CrossRefPubMedPubMedCentral

Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Jicha GA, Cooper G, Markesbery WR (2007) Brain structural alterations before mild cognitive impairment. Neurology 68:1268–1273CrossRefPubMed

Spector SA, Singh KK, Gupta S, Cystique LA, Jin H, Letendre S, Schrier R, Wu Z, Hong KX, Yu X, Shi C, Heaton RK, HNRC Group (2010) 195APOE ε4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors from Anhui province. China AIDS 24:1471–1479CrossRefPubMed

Stebbins GT, Smith CA, Bartt RE, Kessler HA, Adeyemi OM, Martin E, Cox JL, Bammer R, Moseley ME (2007) HIV-associated alterations in normal-appearing white matter: a voxel-wise diffusion tensor imaging study. JAIDS 46:564–573PubMed

Stout JC, Ellis RJ, Jernigan TL, Archibald SL, Abramson I, Wolfson T, McCutchan JA, Wallace MR, Atkinson JH, Grant I, HIV Neurobehavioral Research Center Group (1998) Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal volumetric magnetic resonance imaging study. Neurology 55:161–168

Sun B, Abadjian L, Rempel H, Calosing C, Rothlind J, Pulliam L (2010) Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection. J Neurovirol 16:115–124CrossRefPubMed

Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, Vlassi C, GIulianelli M, Galgani S, Antinori A, Narciso P (2007) Persistance of neuropsychological deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 45:174–182CrossRefPubMed

Valcour V, Shikuma C, Shiramizu B, Watters M, Poff P, Selnes OA, Grove J, Liu Y, Abdul-Majid KB, Gartner S, Sacktor N (2004) Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii aging and HIV cohort. J Neuroimmunol 157:197–202CrossRefPubMed

Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, Drummond F, Vjecha MJ, Hoy J, Miller C, de Oliveira AC P, Pumpradit W, Shlay JC, El-Sadr W, Price RW, INSIGHT SMART Study Group (2010) Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 75:864–873CrossRefPubMedPubMedCentral

Wright PW, Heaps J, Shimony JS, Thomas JB, Ances BM (2012) The effects of HIV and combination antiretroviral therapy on white matter integrity. AIDS 26:1501–1508CrossRefPubMedPubMedCentral

Title: Apolipoprotein E ε4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals
Authors: Sarah A. Cooley
Robert H. Paul
Christine Fennema-Notestine
Erin E. Morgan
Florin Vaida
Qianqian Deng
Jie Ashley Chen
Scott Letendre
Ronald Ellis
David B. Clifford
Christina M. Marra
Ann C. Collier
Benjamin B. Gelman
Justin C. McArthur
J. Allen McCutchan
David M. Simpson
Susan Morgello
Igor Grant
Beau M. Ances
for the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) Group
Publication date: 01-10-2016
Publisher: Springer International Publishing
Published in: Journal of NeuroVirology / Issue 5/2016
Print ISSN: 1355-0284
Electronic ISSN: 1538-2443
DOI: https://doi.org/10.1007/s13365-016-0434-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Apolipoprotein E ε4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2016

Overexpression of thyroid hormone receptor β1 altered thyroid hormone-mediated regulation of herpes simplex virus-1 replication in differentiated cells

Statin modulation of monocyte phenotype and function: implications for HIV-1-associated neurocognitive disorders

2016 Colorado alphaherpesvirus latency society symposium

Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression

Expression profile of nicotinic acetylcholine receptor subunits in the brain of HIV-1 transgenic rats given chronic nicotine treatment

Interleukin-12 (-1188) A/C and interferon-γ (+874) A/T gene polymorphisms in subacute sclerosing panencephalitis patients